XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director

Posted: August 31, 2021 at 2:16 am

Dr. Ziats Joins Clinical Team Involved in Launch and Management of Clinical Studies Across Multiple Indications Dr. Ziats Joins Clinical Team Involved in Launch and Management of Clinical Studies Across Multiple Indications

Read the original post:
XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director

Related Post

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights - March 1st, 2024
Gritstone bio Announces Workforce Reduction - March 1st, 2024
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - March 1st, 2024
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results - March 1st, 2024
ProKidney to Participate in Jefferies Biotech on the Bay Summit - March 1st, 2024
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance - March 1st, 2024
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) - March 1st, 2024
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - March 1st, 2024
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook - March 1st, 2024
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference - March 1st, 2024
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC - March 1st, 2024
Certara Reports Fourth Quarter 2023 Financial Results - March 1st, 2024
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - March 1st, 2024
Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference - March 1st, 2024
GENFIT Announces Revenues and Cash Position as of December 31, 2023 - March 1st, 2024
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau - March 1st, 2024
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results - March 1st, 2024
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results - March 1st, 2024
Spectral AI Appoints Peter M. Carlson as CEO - March 1st, 2024
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference - March 1st, 2024
Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the... - February 21st, 2024
PharmAla Data to be Published in ACS Chemical Neuroscience - February 21st, 2024
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge... - February 21st, 2024
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation - February 21st, 2024
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting - February 21st, 2024
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference - February 21st, 2024
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00... - February 21st, 2024
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024 - February 21st, 2024
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference - February 21st, 2024
NurExone’s Intellectual Property Portfolio Expands - February 21st, 2024
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market - February 21st, 2024
Arvinas Announces Chief Financial Officer Transition - February 21st, 2024
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - February 21st, 2024
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress - February 21st, 2024
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 - February 21st, 2024
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq. - February 21st, 2024
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 - February 21st, 2024
PolTREG appoints Dan Shelly as Chief Business Development Officer - February 21st, 2024
Sanofi: Information concerning the total number of voting rights and shares - January 2024 - February 21st, 2024
Bavarian Nordic delivered record financial results in 2023 - February 21st, 2024
Vistin Pharma ASA: Dividend of NOK 0.75 per share - January 14th, 2024
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status - January 14th, 2024
Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31... - January 14th, 2024
Key information relating to the cash dividend to be paid by Vistin Pharma ASA - January 14th, 2024
QIAGEN N.V. to release results for Q4 2023 and hold webcast - January 14th, 2024
Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries - January 14th, 2024
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split - January 14th, 2024
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference - January 14th, 2024
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference - January 14th, 2024
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference - January 14th, 2024
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study - January 14th, 2024
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting - January 14th, 2024
Boehringer expands production site in Greece for new medicine - January 14th, 2024
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to... - January 14th, 2024
Voting Rights and Shares Capital of the Company - January 14th, 2024
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom - January 14th, 2024
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference - January 14th, 2024
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO - January 14th, 2024
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole - January 14th, 2024
Medicenna Announces Appointment of New Auditor - January 14th, 2024
Axial Therapeutics to Present at Upcoming Conferences - January 6th, 2024
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million - January 6th, 2024
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea - January 6th, 2024
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,... - January 6th, 2024
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones - January 6th, 2024
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T... - January 6th, 2024
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders - January 6th, 2024
Kriya Announces Gene Therapy Program for Thyroid Eye Disease - January 6th, 2024
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis - January 6th, 2024
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 - January 6th, 2024
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 - January 6th, 2024
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital - January 6th, 2024
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD) - January 6th, 2024
BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to... - January 6th, 2024
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones - January 6th, 2024
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development - January 6th, 2024
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program - January 6th, 2024
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 - January 6th, 2024
Societal CDMO Reports Inducement Grants for New Staff - January 6th, 2024
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 6th, 2024